Pre-Conference Workshop Day
Tuesday, August 20
Workshop places are limited to ensure the best learning experience, secure your place today.
8:30 am Morning Check In
09:15 am – 11:45 am | WORKSHOP A
Exploring Novel Lipid-Delivery Systems for Next Generation Applications & Enhanced Therapeutic Outcomes
Synopsis
Bridging Traditional Lipid Systems with EV Innovation:
- Limitations of traditional lipid delivery systems including liposomes, polymeric micelles, and PEGylated lipids.
- Introduction to extracellular vesicles (EVs) as an innovative lipid-based delivery system in terms of delivery efficiency, biocompatibility, and therapeutic potential.
Advances in EV Characterization and Isolation for Therapeutic Delivery:
- Discuss the latest methodologies and technologies for EV characterization and isolation.
- The importance of purity and specificity in EV-based drug delivery systems.
Emerging Trends and Integration Strategies:
- Challenges in scaling EV isolation and characterization for clinical applications.
12:45 pm – 3:15 pm | WORKSHOP B
Creating Seamless Synergy by Optimizing Device Integration With Lipid-Based Drug Delivery Formulations
Synopsis
Understanding Interconnected Challenges:
- Gain insights into the intricate balance required for harmonious device and lipid-based drug formulation development
- Identify challenges in aligning design, functionality, and compatibility
Strategies for Effective Coordination:
- Explore practical strategies for aligning device characteristics with specific formulation requirements
- Address stability, bioavailability, and therapeutic efficacy in the development process
Incorporating Technological Advances:
- Explore the impact of technological advancements on device and formulation coordination
- Stay ahead by integrating cutting-edge technologies into your synchronized development approach
03:25 pm – 05:55 pm | WORKSHOP C
Navigating Clinical Immunogenicity of LNPs: Regulatory Guidelines & Clinical Management in Human Trials
Synopsis
- Explore the regulatory framework surrounding the assessment of clinical immunogenicity of complex biologics, including those delivered via LNPs, ensuring compliance with guidelines and standards set forth by regulatory authorities
- Discuss strategies for effective clinical monitoring of immunogenicity in human trials, including sample collection, and data interpretation to identify, manage, and mitigate potential risks and ensure patient safety
- Discuss how the integrated immunogenicity data from clinical trials and the proposed management and mitigations may impact the label